JP2020532958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532958A5 JP2020532958A5 JP2020507679A JP2020507679A JP2020532958A5 JP 2020532958 A5 JP2020532958 A5 JP 2020532958A5 JP 2020507679 A JP2020507679 A JP 2020507679A JP 2020507679 A JP2020507679 A JP 2020507679A JP 2020532958 A5 JP2020532958 A5 JP 2020532958A5
- Authority
- JP
- Japan
- Prior art keywords
- ribonucleic acid
- acid compound
- cell
- compound according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544220P | 2017-08-11 | 2017-08-11 | |
| US62/544,220 | 2017-08-11 | ||
| US201862671604P | 2018-05-15 | 2018-05-15 | |
| US62/671,604 | 2018-05-15 | ||
| PCT/US2018/046343 WO2019033051A1 (en) | 2017-08-11 | 2018-08-10 | RNA APTAMERS AGAINST THE TRANSFERRIN RECEPTOR (TFR) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532958A JP2020532958A (ja) | 2020-11-19 |
| JP2020532958A5 true JP2020532958A5 (enExample) | 2021-09-16 |
| JP7382919B2 JP7382919B2 (ja) | 2023-11-17 |
Family
ID=65271776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507679A Active JP7382919B2 (ja) | 2017-08-11 | 2018-08-10 | トランスフェリン受容体（ＴｆＲ）に対するＲＮＡアプタマー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11427826B2 (enExample) |
| EP (1) | EP3664814A4 (enExample) |
| JP (1) | JP7382919B2 (enExample) |
| KR (1) | KR20200068647A (enExample) |
| CN (2) | CN111542326B (enExample) |
| AU (1) | AU2018314236B2 (enExample) |
| CA (1) | CA3072575A1 (enExample) |
| WO (1) | WO2019033051A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020208361A1 (en) * | 2019-04-12 | 2020-10-15 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| US20220396794A1 (en) | 2019-06-04 | 2022-12-15 | Apterna Limited | APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR) |
| GB202019692D0 (en) | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| UY40699A (es) | 2023-04-05 | 2024-08-30 | Ionis Pharmaceuticals Inc | Compuestos y métodos para reducir la expresión de pln |
| WO2026011165A1 (en) * | 2024-07-03 | 2026-01-08 | Creyon Bio, Inc. | Transferrin receptor (tfr) aptamers and use thereof |
| CN118879700B (zh) * | 2024-07-18 | 2025-11-07 | 四川大学 | 具有sirt1基因靶向激活功能的框架核酸药物的制备及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6344321B1 (en) * | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| JP2006089471A (ja) | 2004-08-26 | 2006-04-06 | National Institute Of Advanced Industrial & Technology | 癌の治療における抗モータリン２抗体と機能性核酸の使用 |
| AR057807A1 (es) | 2005-09-12 | 2007-12-19 | Novimmune Sa | Formulaciones de anticuerpo anti-cd3 |
| US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
| SG10201808730VA (en) | 2007-04-03 | 2018-11-29 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发（慕尼黑）股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
| JP5142265B2 (ja) | 2007-05-28 | 2013-02-13 | 独立行政法人産業技術総合研究所 | 抗モータリン抗体のパラトープ及びエピトープ |
| EP2511371B1 (en) | 2009-12-10 | 2015-02-25 | National Institute of Advanced Industrial Science And Technology | Anticancer anti-mortalin peptide antibodies |
| KR20130132795A (ko) * | 2010-10-08 | 2013-12-05 | 미나 테라퓨틱스 리미티드 | 짧은 rna 분자 |
| CA2870288A1 (en) | 2012-04-10 | 2013-10-17 | John J. Rossi | Rna aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells |
| US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| US9422563B2 (en) | 2013-03-18 | 2016-08-23 | University Of The Witwatersrand, Johannesburg | CD7 receptor aptamers |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| CN105189544A (zh) | 2013-04-19 | 2015-12-23 | 科瓦根股份公司 | 具有抗肿瘤活性的新颖的双特异性结合分子 |
| US20160326249A1 (en) | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| US9605266B2 (en) | 2014-07-16 | 2017-03-28 | City Of Hope | Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore |
| US10329570B2 (en) | 2014-07-31 | 2019-06-25 | Academia Sinica | Antagonistic PD-1 aptamer and its applications in cancer therapy related applications |
| CN107106697B (zh) | 2014-10-15 | 2021-06-18 | 希望之城 | Pdgfr rna适体 |
| CN107249644A (zh) | 2014-10-15 | 2017-10-13 | 希望之城 | 针对转铁蛋白受体(TfR)的RNA适体 |
| US11460472B2 (en) | 2015-01-27 | 2022-10-04 | Multimmune Gmbh | Quantitative assay for heat shock proteins 70 (Hsp70) protein in body fluids |
| JP6978317B2 (ja) * | 2015-02-11 | 2021-12-08 | ディーキン・ユニバーシティー | ＥｐＣＡＭアプタマー及びそのコンジュゲート |
| US10550394B2 (en) * | 2015-03-31 | 2020-02-04 | City Of Hope | Anti-cancer RNA aptamers |
| US11219635B2 (en) | 2016-02-19 | 2022-01-11 | City Of Hope | Bi-specific aptamer |
| US20200181264A1 (en) | 2017-08-11 | 2020-06-11 | City Of Hope | Bispecific antigen-binding molecule |
-
2018
- 2018-08-10 US US16/637,679 patent/US11427826B2/en active Active
- 2018-08-10 CA CA3072575A patent/CA3072575A1/en active Pending
- 2018-08-10 WO PCT/US2018/046343 patent/WO2019033051A1/en not_active Ceased
- 2018-08-10 JP JP2020507679A patent/JP7382919B2/ja active Active
- 2018-08-10 CN CN201880066428.2A patent/CN111542326B/zh active Active
- 2018-08-10 KR KR1020207006810A patent/KR20200068647A/ko not_active Ceased
- 2018-08-10 EP EP18844104.2A patent/EP3664814A4/en active Pending
- 2018-08-10 CN CN202410700060.8A patent/CN118931907A/zh active Pending
- 2018-08-10 AU AU2018314236A patent/AU2018314236B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022031772A5 (enExample) | ||
| JP5879374B2 (ja) | 筋障害を相殺するための手段と方法 | |
| US11976092B2 (en) | RNA nanostructures, methods of making, and uses thereof | |
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| US20220143197A1 (en) | siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer | |
| US12016930B2 (en) | Skin-permeating carrier containing nucleic acid complex and use thereof | |
| US9050373B2 (en) | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same | |
| Karande et al. | Novel approaches for the delivery of biologics to the central nervous system | |
| US20220372493A1 (en) | Rna nanoparticle for liver cancer treatment | |
| JP2019523302A5 (enExample) | ||
| KR20260005402A (ko) | 암 치료를 위한 조성물 및 방법 | |
| Li et al. | Synergistic metabolic modulation of fibroblast-like synoviocytes via targeted dual prodrug nanoparticles to mitigate rheumatoid arthritis | |
| CN112567037B (zh) | 治疗或诊断tnf相关炎性疾病的tnf靶向适配体及其用途 | |
| JP2001524942A (ja) | アンチセンス・オリゴヌクレオチド薬物 | |
| AU2020365736B2 (en) | Peptide-nucleic acid complex having blood-brain barrier penetration ability and composition comprising same | |
| CN1297253C (zh) | 一种可脑内递药的药物传递系统 | |
| Alkufi et al. | Delivery of nose to brain in the management of cerebral vasospasm in aneurysmal subarachnoid hemorrhage | |
| US20250255976A1 (en) | Cationic biomaterials ameliorate obesity-associated chronic inflammation and focal adiposity | |
| JP2023526328A5 (enExample) | ||
| EP4539831A2 (en) | Targeted nanomedicine for treating lung disorders | |
| JP6950958B2 (ja) | 核酸を含む経腸投与用組成物 | |
| Liao | Zhilin Wu1, Chen Chen1Ε, Jiajia Luo1, Jacques RJ Davis1, Bo Zhang2, Liang Tang2, Wei Shi2 & | |
| HK40082399A (en) | Rna nanoparticle for liver cancer treatment | |
| HK40068943A (en) | Peptide-nucleic acid complex having blood-brain barrier penetration ability and composition comprising same | |
| JP2010518036A (ja) | アポリポタンパク質による血液脳関門を介しての薬剤の輸送 |